Patents Examined by Nianxiang Zou
  • Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
    Patent number: 10849971
    Abstract: Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: December 1, 2020
    Assignee: GlobeImmune, Inc.
    Inventors: Thomas H. King, David Apelian
  • Serologic test for therapy control of HPV16 positive carcinoma
    Patent number: 10852303
    Abstract: A method for therapy control of HPV16 positive carcinoma, an antibody for use in the corresponding diagnostic method as well as a test for performing the method. In particular, a serologic method for monitoring the development of the amount of antibodies in samples, which were taken from a patient before and after the treatment of a HPV16 positive carcinoma over a predetermined period of time. In addition, an immunologic test in the form of a kit, with which the method can be performed.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: December 1, 2020
    Assignee: ABVIRIS DEUTSCHLAND GMBH
    Inventor: Ralf Hilfrich
  • Recombinant viral vectors
    Patent number: 10844095
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: November 24, 2020
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
  • Engineered influenza antigenic polypeptides and immunogenic compositions thereof
    Patent number: 10844097
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 24, 2020
    Assignee: Sanofi Pasteur Inc.
    Inventors: Tod Strugnell, Eliud Oloo
  • Oncolytic vaccinia virus mutants and using same for cancer treatment
    Patent number: 10842835
    Abstract: Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: November 24, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Bertram Jacobs, Heather Koehler, William Arndt, Karen Kibler, Kelly Trainor, Chandra Mitnik, Jeffrey Langland
  • Therapeutic HPV18 vaccines
    Patent number: 10844096
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 24, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Evelien Margaretha Bunnik, Jerôme Hubertina Henricus Victor Custers, Gerrit Christiaan Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
  • Compositions of and methods for in vitro viral genome engineering
    Patent number: 10837004
    Abstract: The present disclosure relates to a method of in vitro engineering of nucleic acids. This disclosure further relates to in vitro engineering of viral genomes and to the improvement of viral properties by in vitro genomic engineering of viral genomes. Specifically, the disclosure relates to in vitro viral genomic digestion using RNA-guided Cas9, the assembly of a recombinant genome by the insertion of a DNA or RNA fragment into the digested viral genome and transformation of a host cell with the recombinant genome. This method also related to in vitro engineering for error correction of nucleic acids.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: November 17, 2020
    Assignee: C3J Therapeutics, Inc.
    Inventors: Kyle C. Cady, E. Magda Barbu, Christen G. DiPetrillo
  • Anti-vaccine using sendai virus as vector
    Patent number: 10828359
    Abstract: Provided in the present application are a recombinant sendai virus vector vaccine expressing immunodominant antigens of Mycobacterium tuberculosis, and can be used as therapeutic and preventive antituberculosis vaccine.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: November 10, 2020
    Assignees: Shanghai Public Health Clinical Center, Fudan University, ID Pharma Co., Ltd.
    Inventors: Xiao-Yong Fan, Tsugumine Shu, Zhi-Dong Hu, Douglas B. Lowrie
  • RSV F protein mutants
    Patent number: 10821171
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: November 3, 2020
    Assignee: Pfizer Inc.
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
    Patent number: 10821143
    Abstract: Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: November 3, 2020
    Assignee: YALE UNIVERSITY
    Inventors: Anthony N. Van Den Pol, Guido Wollmann
  • BK virus specific T cells
    Patent number: 10821134
    Abstract: Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: November 3, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Katy Rezvani, Elizabeth Shpall, Muharrem Muftuoglu
  • Cancer therapy with a parvovirus combined with bevacizumab
    Patent number: 10813959
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: October 27, 2020
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karis-Universität Heidelberg
    Inventors: Karsten Geletneky, Jean Rommelaere, Wolfgang Wick, Antje Wick, Michael Dahm
  • Hand, foot, and mouth vaccines and methods of manufacture and use thereof
    Patent number: 10806782
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 20, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
  • Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages
    Patent number: 10808284
    Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: October 20, 2020
    Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHQUEST, L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Marc Eloit, Nicolas Torno, Jean Deregnaucourt, Marion Mouton, Isabelle Heard, Philippe Perot
  • Adeno-associated virus particle with mutated capsid and methods of use thereof
    Patent number: 10806802
    Abstract: A recombinant adeno-associated virus (rAAV) particle with a mutated capsid protein is provided. In particular, the present disclosure provides methods of delivering a therapeutic agent to a muscle, airway, liver, central nervous system, retina or lung cell in a subject, and methods of treating or preventing infectious, acquired or genetic disease, with said rAAV particle.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 20, 2020
    Assignees: University of Guelph, Ottawa Hospital Research Institute
    Inventors: Sarah Wootton, Laura van Lieshout, Bernard Claude Frank Thebaud, Martin Hubert Kang
  • Method and composition for treating cancer or skin lesion using a vaccine
    Patent number: 10799574
    Abstract: A method for treating or reducing the incidence of recurrence of cancer, benign tumors or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: October 13, 2020
    Assignee: HPVVAX. LLC
    Inventor: Tim Ioannides
  • Method of inducing an oncolytic effect on tumor cells using Zika virus
    Patent number: 10786537
    Abstract: The present invention provide for methods of inducing an oncolytic effect on tumor cells using Zika virus. The invention also provides for inducing an oncolytic effect on brain tumors and treating brain tumors, and in particular, glioblastomas and neuroblastoma. The treatment involves the administration of Zika virus, which has an oncolytic effect on the tumor cells.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Vaithilingaraja Arumugaswami, Joshua Breunig
  • Biopesticide
    Patent number: 10779543
    Abstract: A nucleopolyhedrovirus (NPV), a composition comprising the NPV, and a method comprising the use of the NPV is provided. The NPV was isolated from Cryptophlebia peltastica and has insecticidal activity against several species of moths within the tortricid tribe, Grapholitini. The NPV or composition may be suitable for use in controlling insect populations, particularly populations of insects that infest plants.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: September 22, 2020
    Assignees: RHODES UNIVERSITY, CITRUS RESEARCH INTERNATIONAL (PTY) LTD, RIVER BIOSCIENCE (PTY) LTD
    Inventors: Sean Moore, Martin Hill, Caroline Knox, Tamryn Marsberg, Michael Jukes, Boguslaw Szewczyk, Lukasz Rabalski, Craig Chambers
  • Composition comprised of antigen linked to a TNF superfamily ligand
    Patent number: 10774149
    Abstract: The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of TNF SuperFamily (TNFSF) ligands. The TNFSFs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of CD40 ligand (CD40L, TNFSF5) is provided. Other similar fusion proteins are also disclosed. The fusion proteins can be delivered to a host as isolated proteins, as nucleic acids used directly in DNA vaccination or carried and expressed by a viral vector such as adenovirus. In addition to use as a vaccine to prevent or ameliorate disease caused by an infectious agent, compositions of the invention may be used for the treatment of ongoing infection or for cancer immunotherapy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Geoffrey W. Stone, Richard S. Kornbluth
  • HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
    Patent number: 10772947
    Abstract: The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 15, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ramesh V. Chintala, Akhilesh Bhambhani